Protara Therapeutics, Inc. short interest in 2021
In 2021, Protara Therapeutics, Inc.'s disclosed short interest ran from 0.97% of shares outstanding on 15 Jan 2021 to 3.37% on 31 Dec 2021, a change of +2.40 percentage points. The year's high was 3.48% on 15 Dec 2021 and its low 0.97% on 15 Jan 2021, averaging 2.11% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.31 days on 13 Aug 2021. Full history: Protara Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 0.97% (15 Jan 2021)
- End of year
- 3.37% (31 Dec 2021)
- Change
- +2.40 pp
- High
- 3.48% (15 Dec 2021)
- Low
- 0.97% (15 Jan 2021)
- Average
- 2.11%
- Highest days to cover
- 6.31 (13 Aug 2021)
- SEC filings marked
- 6
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 0.97% | 1.33 | |
| 29 Jan 2021 | 1.21% | 1.98 | |
| 12 Feb 2021 | 1.21% | 1.64 | |
| 26 Feb 2021 | 1.38% | 1.87 | |
| 15 Mar 2021 | 1.85% | 2.23 | 10-K filed |
| 31 Mar 2021 | 2.57% | 2.84 | |
| 15 Apr 2021 | 2.54% | 3.29 | |
| 30 Apr 2021 | 3.06% | 1.44 | |
| 14 May 2021 | 2.73% | 1.97 | 10-Q filed |
| 28 May 2021 | 2.70% | 5.59 | |
| 15 Jun 2021 | 2.77% | 2.31 | |
| 30 Jun 2021 | 1.32% | 1.00 | |
| 15 Jul 2021 | 1.69% | 2.17 | |
| 30 Jul 2021 | 1.72% | 4.46 | |
| 13 Aug 2021 | 1.68% | 6.31 | 10-Q filed, results (8-K) |
| 31 Aug 2021 | 1.84% | 1.31 | |
| 15 Sep 2021 | 1.80% | 3.97 | |
| 30 Sep 2021 | 1.15% | 1.00 | |
| 15 Nov 2021 | 2.84% | 2.69 | 10-Q filed, results (8-K) |
| 30 Nov 2021 | 2.63% | 3.43 | |
| 15 Dec 2021 | 3.48% | 5.71 | |
| 31 Dec 2021 | 3.37% | 3.69 |
See also: Protara Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.